Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2019-0026
Abstract: Over the past 10 years, sorafenib has been the only systemic agent approved for the treatment of patients with unresectable hepatocellular carcinoma. Recently, lenvatinib was demonstrated noninferior to sorafenib, and regorafenib and ramucirumab were demonstrated… read more here.
Keywords: hepatocellular carcinoma; treatment; carcinoma failing; sorafenib ... See more keywords